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Abstract
All countries in the European Region of the World Health Organization (WHO) have renewed their commitment to eliminate measles
transmission by 2015. Measles elimination is a feasible target but requires vaccination coverage above 95% with two doses of a measles-
mumps-rubella vaccine (MMR) in all population groups and in all geographical areas. Measles has re-emerged in the EU recently, due to
suboptimal immunization levels that led to accumulation of susceptible populations over the last years. In fact, while an overall decreasing
trend had been observed until 2009, the number of cases increased by a factor of four between2010 and 2011. According to vaccination
coverage data reported to the WHO, between 2000 and 2010, almost 5 million individuals in the EU in the age group 2–12 had not had
MMR vaccination. Catch-up vaccination activities for susceptible populations are paramount in order to reach the elimination goal, but
only feasible if a multi-component approach is put in place quickly and efficiently. Advocacy and communication are key strategic areas.
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Epidemiology of measles in Europe
All countries in the European Region of the World Health
Organization (WHO), which includes EU and EEA/EFTA
countries, have renewed their commitment to eliminate
measles transmission by 2015 [1]. The incidence of measles
in Europe had decreased dramatically since 1998, thanks lar-
gely to good vaccination coverage achieved through the rou-
tine immunization and two-dose vaccination policies of most
European countries [2]. Despite some large outbreaks in
several member states, this overall decreasing trend was
observed until 2010, [3–9] (Fig. 1). In 2011, 30 567 cases of
measles were reported by the 29 contributing EU and EEA/
EFTA countries [9]. This is similar to the number of cases in
2010 (30 264 cases) and constitutes a four-fold increase
compared with 2009 (7175 cases) and 2008 (7817).
The dramatic increase in 2010 was primarily due to a
large outbreak in Bulgaria that started at the end of 2009
and exploded in 2010, with more than 24 000 reported
cases and 24 deaths. The cases were mainly infants, children
and young adults. The majority of cases ( 90%) were part
of the Bulgarian Roma community and almost all cases (95%)
had not received the full course of measles, mumps and
rubella (MMR) vaccination [10,11].
In 2011, France reported more than half of all reported
cases, with nearly 15 000 cases and six deaths. Sixteen
patients developed neurological complications and 650 suf-
fered severe respiratory complications. A sharp decrease in
the number of reported cases began in May 2011 [9].
Together with France, four countries (Italy, Romania,
Spain and Germany) accounted for more than 90% of all
measles cases reported in 2011 [9].
Age-specific incidence of measles
According to the ECDC Annual Epidemiological Report, in
each year from 2005 to 2009 the most affected age groups
in the EU and EEA/EFTA countries were 0–4 year olds
followed by 5–14 year olds [2,12–15]. More detailed data
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from 2011 [9] showed that the highest incidence was among
infants under 1 year, followed by children aged between 1
and 4 years. Overall, age-specific notification rates were rela-
tively high up to age 25 years, suggesting a significant addi-
tional circulation of measles virus amongst adolescents and
young adults, as well as those aged less than 5 years.
Vaccination Coverage and Susceptibility to
Measles in Europe
Countries report their MMR vaccine coverage to the WHO,
and these data are publicly available through WHO’s Cen-
tralized information System for Infectious Diseases (CISID)
[16].
So far, only some member states in the EU have been able
to attain and maintain 95% MMR vaccination, as is required
to reach the elimination goal. [16].
We made an attempt to calculate how many children are
not vaccinated against MMR in the EU using data from CISID
and Eurostat [17], following a methodology described in the
Annex.
Taking into account the vaccination coverage reported to
the WHO in 2000, the birth cohort for 1998 (1994 for Ger-
many) accumulated 486 559 susceptible individuals in all EU
countries. Birth cohorts 1998–2008 (1994–2004 in Germany)
had 4 929 607 individuals in the age group 2–12 years who
had missed MMR vaccination in the EU between 2000 and
2010. This number is approximately the equivalent of one
EU birth cohort (Annex 3, Fig. 2).
This calculation should be taken as a rough estimate, as it
relies on assumptions described in the Annex (e.g. using
MMR1 coverage). Also, countries use different methodolo-
gies and definitions for assessing vaccination uptake and
direct comparisons of coverage between countries should be
made with caution.
In addition, this calculation has to be considered as a con-
servative estimate of the susceptible population, as an addi-
tional 5% of vaccinated children could be at risk, for example
through primary vaccine failure, a physiologically insufficient
immune response to the vaccine, low vaccination levels for
MMR2, and the absence of significant catch-up programmes.
As part of the European Sero-Epidemiology Network 2
(ESEN2), Andrews et al. [18] assessed age-specific measles
susceptibility in 17 European countries. They collected
national serum banks between 1996 and 2004 and tested
them for IgG in a standardized way. In order to compare
their data with the WHO European Region targets for mea-
sles elimination, age-stratified population susceptibility target
levels were set at <15% in those aged 2–4 years, <10% in
5–9 year olds and <5% in older age groups.
Seven countries (the Czech Republic, Hungary, Luxem-
bourg, Spain, Slovakia, Slovenia and Sweden) were very close
to elimination targets. Lithuania and Malta had susceptibility
levels exceeding WHO targets in some older age groups,
indicating possible gaps in protection. Seven countries
(Belgium, Bulgaria, Cyprus, England and Wales, Ireland, Latvia
and Romania) were deemed at risk of epidemics as a result
of high susceptibility in children and, in some cases, adults.
This study pointed out that current efforts were insufficient
to eliminate measles by 2010, as happened to be the case.
In the case of Bulgaria, the study showed that 30.7% of
children aged 2–4 years, 25.9% of those aged 5–9 and 20.7%
of 10–19 year olds were seronegative for measles (while
WHO coverage data for the first MMR dose was estimated
at 94.7% in 2004 [16]). This high proportion of children who
were susceptible to measles, together with the concentration
of susceptible individuals in population subgroups, in this case
the Bulgarian Roma population, were the main drivers for
the huge 2009–2010 outbreak [10].
Measles vaccination schedules in Europe are set at national
and sometimes local levels. They differ in the way they are
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FIG. 2. Progressive accumulation of children susceptible to measles
and birth cohorts 1998–2008 (1994–2004 for Germany) in the EU
and Norway. Sources: CISID and Eurostat.
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FIG. 1. Reported measles cases in the EU and Norway from 2005
to 2011.
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planned, organized and conducted [19]. The WHO recom-
mends that the minimum age to start MMR vaccination in
countries with low transmission is 12 months [20]. In the
EU, the minimum age for the first dose is 12 months, except
for Germany (11 months) and France (9 months for children
in day-care), and all first doses have been given by
18 months of age. The age of the second dose of MMR has a
wide range of variation, from 12 months to 15 years [19].
Moving countries can pose challenges for immunization if
an individual starts the vaccination programme in one coun-
try and continues it in another. Many Eastern European
countries give their second MMR between 6 and 12 years of
age (with the vast majority at 6 years of age). Therefore a
4-year-old child moving from an Eastern European country to
a country where the second dose is given before 4 years of
age would miss their vaccination, as has been documented in
the UK [21]. In the light of such examples of common cross-
border movement, a common European schedule could have
a significant positive impact on European vaccination.
Determinants of Measles Outbreaks and
Potential Areas of Intervention
Resurgence of measles in Europe is the result of the accumu-
lation of a susceptible population over the last decades. Slow
accumulation in consecutive birth cohorts may generate large
outbreaks, with adolescents and young adults primarily
affected. Confinement of susceptible individuals in defined
population pockets with a certain degree of segregation (eth-
nic groups, religious communities, etc.), usually results in an
outbreak involving younger children, as occurs in completely
unvaccinated populations. Both age patterns have been
observed during the recent European outbreaks [10,11].
Even though the epidemiological circumstances leading to
measles resurgence are clear, the reasons underlying such
circumstances are more complex and worth investigation.
Organizational issues, combined with social, psychological
and behavioural determinants, are the leading causes of sub-
optimal immunization levels. Europe is now experiencing
what is called the vaccine paradox, in which vaccines are
somehow victims of their own success. In fact, following
the introduction of an effective and safe vaccine, vaccination
coverage increases. This results in a dramatic decrease in
the incidence of disease, followed by a decrease in the per-
ceived risk of the disease and its complications. As the dis-
ease is no longer remembered as dangerous, real or
alleged adverse events following immunization (AEFI)
become the main concern. Even healthcare workers pay
less attention to the disease and its consequences, leading
to less effective communication with parents of small
children.
Risk perception is highly influenced by relatively small yet
very active anti-vaccination movements. The arguments of
anti-vaccine groups confuse scientific evidence (e.g. on side-
effects), with their views being put in a manner that makes it
very difficult to differentiate between the two, often effec-
tively using emotional communication [22]. Tactics used by
this movement have been categorized by Kata [23] in four
categories. (i) Skewing the science, while trying to create
legitimacy for unfounded or discredited theories of harm.
This is achieved by, on the one hand, denigrating legitimate
scientific studies (and the scientific process in general) that
fail to support anti-vaccine positions, and on the other hand,
legitimating anti-vaccine theories through pseudoscientific
conferences. (ii) Shifting hypotheses and presenting new the-
ories regarding vaccines causing harm, when evidence does
not support such theories, from MMR to thimerosal, to
other ‘toxins’, to ‘too many, too soon’. (iii) Censorship (sup-
pressing dissenting opinions). (iv) Attacking the opposition
(attacking critics both via personal insults and by legal
actions).
Besides ignoring or avoiding scientific evidence, those that
are anti-vaccination have also been offering tropes (mottos
or phrases used recurrently) to create fear, uncertainty and
doubt about vaccines. Claims such as not being ‘anti-vaccine’
but ‘pro-safe vaccines’, that vaccines are toxic or unnatural
or claiming that those supporting vaccines do so because
they are hired by pharmaceutical companies are commonly
used to spread scepticism. Recognizing such anti-vaccine
tropes is essential in order to critically evaluate the informa-
tion and misinformation encountered online [23].
These groups are particularly efficient in spreading their
views on the Internet. According to recent studies, the
majority of websites popping up after a generic Google
search (such as using the term ‘vaccination’) can be classified
as anti-vaccination [24]. Moreover, even a short search for
the term ‘vaccination’ in Google can lead to considerable
changes in perception of risk [25].
A major argument against MMR vaccination is its alleged
potential link to autism. Wakefield generated a worldwide
scare over the MMR vaccine with his publication in the Lan-
cet in 1998 [26] (article retracted). Since then, numerous
studies have failed to show a link between the MMR vaccine
and autism [27–30] and it has now been demonstrated that
this link was artificially manufactured by Wakefield by mis-
reporting the cases [31]. The article was withdrawn from
the Lancet in 2010. However, a significant decrease in vacci-
nation trust, and therefore coverage, in several parts of the
world, especially in the UK, had already occurred [32].
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Anti-vaccination attitudes are often supported by religious
or philosophical beliefs. Religious minorities, such as the
Orthodox Jewish or Christian Reformed Churches, and an-
throposophist groups represent pockets of under-immunized
populations that may easily generate outbreaks due to
frequent contacts between unvaccinated members of such
communities [33].
Moreover, during the last years, measles has spread
among ethnic groups that have poor access to healthcare
and health promotion, such as the Roma population [34]. In
Bulgaria, a number of circumstances converged simulta-
neously to precipitate the outbreak: virus importation from
Germany, health system and socio-economic reform, social
marginalization, crowded housing conditions and a high
degree of mobility among Roma communities [34]. Control
measures implemented included a supplementary MMR vacci-
nation campaign in the affected regions (supplied by the Min-
istry of Health and offered free of charge through routine
immunization services) targeting all individuals from
13 months to 30 years of age who had not received the
complete two-dose vaccination regimen. Additionally, special
outreach teams consisting of regional epidemiologists, health
inspectors and local Roma community leaders were deployed
in the campaign to immunize the Roma community. The
2009 to 2010 outbreak has subsided, with Bulgaria reporting
only 157 cases in 2011 [9]. All activities put in place for con-
trolling the outbreak should be reinforced and sustained in
the future in order to avoid this event being repeated.
A small percentage of healthcare workers are against vac-
cination in principle, especially among providers of homeo-
pathy and complementary medicines [35]. In the case of
measles, the attitudes and practices of healthcare workers in
Europe appear at times variable: misconceptions regarding
the severity of the disease or the safety of MMR persist not
only among parents, but also among doctors and nurses (35,
36). A major problem appears to be insufficient knowledge
on vaccine product safety and vaccination schedules, with
subsequent misleading, unclear or untrue messages commu-
nicated to parents.
There is definitely not a one-size-fits-all solution for
improving MMR vaccine coverage in Europe. However, there
is the need to assess the level of protection in the older age
groups (e.g. more than 5 years) and fill immunization gaps in
this population with catch-up programmes or supplementary
immunization activities (SIA) almost everywhere in Europe.
Additional effort is also required to address the needs of
marginalized and hard-to-reach groups.
A multi-component approach is essential to reach the
vaccination coverage required for measles and rubella
elimination. The following priority areas for intervention,
both on the supply and demand sides, should be taken
into account.
• Improving the quality of vaccine supply, by facilitating
access to healthcare in general and to vaccine providers in
particular, is paramount. To this end, financial and human
resources should be specifically increased for MMR supple-
mentary immunisation activities.
• Advocacy activities among decision makers and healthcare
workers should raise awareness of the importance of elimi-
nating measles and rubella.
• Communication activities involving the general public, tai-
lored to local specific needs, should be put in place in order
to increase the demand for immunization. This also implies
the distribution of vaccination reminders to parents. New
communication tools and social media may play some role in
counteracting anti-vaccination movements.
In conclusion, the European commitment to eliminate mea-
sles and rubella by 2015 should be addressed in a global con-
text, where the European Region, together with the
American and the Western Pacific Region, should be leading
the global process of measles and rubella elimination. This is
a challenging but still feasible goal. Improved vaccine supply,
advocacy and communication are key strategic areas of inter-
vention, necessary to initiate and sustain those extraordinary
vaccination activities (catch-up, SIAs) without which such a
goal will be missed. Again.
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Appendix
To calculate a rough number of the amount of susceptible chil-
dren (not vaccinated with one MMR dose (MMR1) at 2 years
of age) we used the birth cohorts 1998–2008 for 26 EU coun-
tries and Norway. For Germany, because vaccine coverage
assessment is carried out at school entry (around 6 years), we
used birth cohorts 1994–2004. We chose coverage of MMR1
due to the fact that the recommended age for the second dose
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of MMR vaccine varies considerably between countries and
available data on MMR2 coverage are scarce.
We used CISID data on % of infants vaccinated against
MMR1 for the years 2000–2010 (Annex 1). For some years
in some countries there were no data in CISID. In that case,
we calculated the average of the previous and subsequent
available data around the missing one. If there were no data
for the last years, the last available year was used. Moreover,
we extracted from Eurostat demographic data on children
aged 2 years per country from 2000 to 2010, which is the
age when vaccination coverage is estimated in most coun-
tries, and children aged 6 years for Germany (Annex 2).
Annex 1. Percentage of infants vaccinated against first dose of MMR (MMR1) for the years 2000–2010, CISID data
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Austria 74.7 78.5 78.5 78.8 73.5 91 80 77 83 76 79.1
Belgium 82.2 82.2 82.2 82.2 82.2 88 91.9 91.9 93a 94 94
Bulgaria 88.6 90.1 92.1 95.5 94.7 96.2 95.7 96 95.9 96.1 96.5
Cyprus 85 85 85 86 86.3 86.3 87 87 87 87 87
Czech Republic 98 98 99 99.1 96.9 98.2 98.2 98.2 98.2 98.2 98.2
Denmark 100 94 100 96 96 95 100 89 86.5a 84 85
Estonia 93 94.7 95.2 95.2 95.5 95.9 96.1 95.5 95 95 95.1
Finland 96 96 95.8 97 97 97 97 98 97 98.5 98.5a
France 84 85 85 86 86 89.5a 89.5a 93 87 90.1 90.1
Germany 91.7 91 91 92 92.5 93.3 94 94.5 95.4 95.9 96
Greece 88 88 88 88 88 93.5a 93.5a 93.5a 98.9 98.9 98.9a
Hungary 100 100 99.9 99.9 99.9 99.9a 99.9a 99.9 99.9 99.8 99.9
Ireland 79 73 72.5 78.5 81.1 84.2 86.2 87.02 89 90.4 90
Italy 74 76.5 77 83 84 87.2 87 87a 87a 87a 87a
Latvia 96.9 97.9 98.3 98.6 98.7 95 95.3 97 96.6 95.7 90.1
Lithuania 97 97.4 97.9 97.7 97.7 97.2 96.6 96.9 97 96 96.1
Luxembourg 91 91 95.4 95.4 95.4 95.4 95.8a 96.2 96.2 96.2 96.2
Malta 74 65 65 90 87.4 86 94 79 78 82 72.5
Netherlands 95 95 96 95.7 96.3 96.3 96.1a 95.9 96.2 96.2 95.9
Norway 92 93 88 84 88 90 91 92 93 92 93
Poland 97 97.2 97.6 97.5 97.4 98.2 98.2 98.3 98.3a 98.3 98.2
Portugal 87 86.8 91.9 96.3 94.8 92.6 96.7 95 96.6 95 96
Romania 98 97.8 98.2 97.2 97.1 96.7 96.9a 97.1 96.1a 96.1a 95
Slovakia 98 98.6 98.6 98.6 98 98 98.4 98.8 99 99 98.5
Slovenia 95.2 94 93.5 86.7 94 95.5a 96.1 95.6 96 95 95
Spain 94 96 96.6 97.2 97.3 96.8 96.9 97.1 97.8 97.5 95.1
Sweden 94.2 88.5 95 95 94.5 95.4 95.4 96.2 96.2 96.7 96.5
aUnited Kingdom 99 98.7 83 80 81 82.1 84.9 86.2 85.5 86 93
aData not available on CISID: we calculated the average of the previous and subsequent available data around the missing
one. If there were no data in the last years, the last available year was used.
MMR, measles, mumps and rubella vaccine; CISID, Centralized Information System for Infectious Diseases.
Annex 2. Population at 2 years of age in EU per country (at 6 years for Germany), Eurostat
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Austria 85 029 82 227 79 290 79 881 77 496 80 770 79 354 80 995 79 971 79 715 78 003
Belgium 116 529 114 887 114 257 116 079 114 823 112 949 114 562 118 426 120 831 124 289 125 846
Bulgaria 62 951 64 871 68 105 66 608 67 413 66 199 66 920 69 315 70 509 72 822 73 874
Cyprus 9500 9141 8563 8529 8387 7849 8061 8345 8362 8895 8645
Czech Republic 90 220 90 136 87 964 89 256 91 301 93 126 94 062 97 834 102 988 106 518 115 180
Denmark 68 155 66 775 66 912 67 722 65 885 64 607 65 155 65 080 64 993 66 062 65 205
Estonia 12 090 11 757 12 044 12 922 12 518 12 910 12 940 13 893 14 262 14 797 15 694
Finland 59 272 56 988 57 679 56 876 56 293 55 850 56 978 58 089 58 114 59 505 59 415
France 741 209 757 673 764 660 796 466 789 433 777 830 772 882 780 597 788 026 807 529 792 766
Germanya 814 607 782 802 775 663 803 429 819 102 794 354 777 473 773 550 739 386 721 364 708 024
Greece 101 697 99 873 99 684 101 423 101 937 103 532 104 789 105 932 107 909 112 413 112 265
Hungary 98 300 95 398 93 212 97 601 96 217 96 096 94 285 95 131 97 688 100 076 97 748
Ireland 53 785 55 184 56 123 55 862 54 687 58 542 60 521 61 082 63 236 67 372 71 447
Italy 522 615 521 284 525 677 533 305 534 563 543 129 550 865 561 735 559 638 567 379 569 438
Latvia 18 220 17 931 19 050 20 044 19 446 19 949 20 926 20 391 21 823 22 775 23 739
Lithuania 37 114 36 349 35 880 33 755 31 228 29 751 30 266 30 119 30 270 30 987 31 990
Luxembourg 5715 5498 5776 5835 5592 5550 5469 5711 5582 5774 5722
Malta 4827 4530 4358 4294 3944 3921 3938 3833 4233 3917 3911
Netherlands 194 547 201 787 203 816 208 833 205 052 202 834 200 902 193 486 187 173 185 053 182 106
Norway 60 699 59 148 59 953 59 963 57 612 56 616 57 865 58 242 58 391 60 250 60 148
Poland 408 478 392 046 380 856 376 490 362 489 352 386 348 971 353 924 362 331 372 660 386 811
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Annex 2. Continued.
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Portugal 105 574 105 168 111 759 109 250 111 616 113 163 111 403 108 563 109 055 105 155 102 112
Romania 229 957 230 290 223 377 222 819 211 733 206 453 208 602 212 452 217 538 216 455 212 189
Slovakia 58 574 56 178 55 632 53 919 50 804 50 458 51 353 53 383 54 108 53 648 54 231
Slovenia 18 343 18 057 17 670 18 445 17 776 17 820 17 431 18 127 18 361 19 361 20 392
Spain 365 624 368 176 383 169 405 567 423 357 428 423 451 153 461 899 471 401 477 293 494 837
Sweden 91 008 90 304 89 779 92 180 93 204 97 625 100 798 103 091 103 797 108 612 110 130
United Kingdom 722 052 705 384 689 121 671 189 662 072 670 956 692 756 710 851 724 676 744 168 772 266
Total 5 156 691 5 099 842 5 090 029 5 168 542 5 145 980 5 123 648 5 160 680 5 224 076 5 244 652 5 314 844 5 354 134
aGermany population at 6 years.
For each birth cohort and country, we multiplied the number of children by the vaccination coverage. The resultant number
was the number of children vaccinated by country and year and the difference between the birth cohort and the children vac-
cinated was the susceptible children by country and year. Then we added up all the susceptible children for all the countries
by birth cohort and finally by year.
Annex 3. Number of susceptible children at 2 years of age per year and country for birth cohorts 1998–2008 (1994–2004 in
Germany)
2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 Total
Austria 21 512 17 679 17 047 16 935 20 536 7269 15 871 18 629 13 595 19 132 16 303 184 508
Belgium 20 742 20 450 20 338 20 662 20 438 13 554 9 280 9 593 8 519 7 457 7 551 158 583
Bulgaria 7176 6422 5380 2997 3573 2516 2878 2773 2891 2840 2586 42 031
Cyprus 1425 1371 1284 1194 1149 1075 1048 1085 1087 1156 1124 12 999
Czech Republic 1804 1803 880 803 2830 1676 1693 1761 1854 1917 2073 19 095
Denmark – 4007 – 2709 2635 3230 – 7159 8774 10 570 9781 48 865
Estonia 846 623 578 620 563 529 505 625 713 740 769 7 112
Finland 2371 2280 2423 1706 1689 1676 1709 1162 1743 893 891 18 542
France 118 593 113 651 114 699 111 505 110 521 81 672 81 153 54 642 102 443 79 945 78 484 1 047 308
Germany 67 612 70 452 69 810 64 274 61 433 53 222 46 648 42 545 34 012 29 576 28 321 567 905
Greece 12 204 11 985 11 962 12 171 12 232 6781 6864 6939 1187 1237 1235 84 796
Hungary – – 93 98 96 96 94 95 98 200 98 968
Ireland 11 295 14 900 15 434 12 010 10 336 9250 8352 7928 6956 6468 7145 110 073
Italy 135 880 122 502 120 906 90 662 85 530 69 521 71 612 73 026 72 753 73 759 74 027 990 177
Latvia 565 377 324 281 253 997 984 612 742 979 2350 8463
Lithuania 1113 945 753 776 718 833 1029 934 908 1239 1248 10498
Luxembourg 514 495 266 268 257 255 230 217 212 219 217 3151
Malta 1255 1586 1525 429 497 549 236 805 931 705 1074 9592
Netherlands 9727 10 089 8153 8980 7648 7505 7835 7933 7113 7032 7466 89 481
Norway 4856 4140 7194 9594 6913 5662 5208 4659 4087 4820 4210 61 345
Poland 12 254 10 977 9141 9412 9425 6343 6281 6017 6160 6335 6963 89 308
Portugal 13 725 13 882 9052 4042 5804 8374 3687 5428 3708 5258 4084 77 045
Romania 4599 5066 4021 6239 6140 6813 6467 6161 8593 8550 10 609 73 258
Slovakia 1171 786 779 755 1016 1009 822 641 541 536 813 8870
Slovenia 880 1083 1149 2453 1067 882 680 805 734 968 1020 11 721
Spain 21 937 14 727 13 028 11 559 11 431 13 710 13 986 13 395 10 371 11 932 24 247 160 322
Sweden 5278 10 385 4489 4609 5126 4491 4637 3917 3944 3584 3855 54 316
United Kingdom 7221 8747 117 151 134 238 125 794 120 101 104 606 98 097 105 078 104 184 54 059 979 274
Total 486 559 471 409 557 857 531 983 515 652 429 590 404 393 377 581 409 747 392 233 352 601 4 929 607
Each cell is calculated as the population by year and country (Annex 2) multiplied by 100 – % coverage for that year and coun-
try (Annex 1).
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